Market capitalization | $8.37m |
Enterprise Value | $-18.36m |
P/E (TTM) P/E ratio | 3.95 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | -1.15 |
P/S ratio (TTM) P/S ratio | 0.52 |
P/B ratio (TTM) P/B ratio | 0.33 |
Revenue (TTM) Revenue | $16.02m |
EBIT (operating result TTM) EBIT | $2.64m |
As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.
2 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast:
2 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 16 16 |
-
|
|
Gross Profit | 16 16 |
10,733%
10,733%
|
|
EBITDA | 2.70 2.70 |
132%
132%
|
EBIT (Operating Income) EBIT | 2.64 2.64 |
130%
130%
|
Net Profit | 3.59 3.59 |
129%
129%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Brian Strem |
Employees | 12 |
Founded | 1998 |
Website | www.kiorapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.